These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3736737)

  • 1. Total and intrarenal flow distribution in healthy subjects: technique, acute effects of ibopamine and of indoramin.
    Britton KE; Nawaz MK; Nimmon CC; Mlodkowska E; Carroll M; Horne T; Granowska M
    Nephron; 1986; 43(4):265-73. PubMed ID: 3736737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of effect of ibopamine, a dopamine pro-drug, on renal function in normal subjects.
    Harvey JN; Worth DP; Brown J; Lee MR
    Br J Clin Pharmacol; 1984 Jun; 17(6):671-7. PubMed ID: 6378230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral and renal effects of ibopamine in normal subjects.
    Incerti PL; Badalamenti S; Lorenzano E; Graziani G; Morganti A; Salerno F; Ghirardi P
    Arzneimittelforschung; 1986 Feb; 36(2A):405-7. PubMed ID: 3518727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ibopamine on systemic, pulmonary and regional hemodynamics. Experimental investigations in anesthetized dogs.
    Merlo L; Ghirardi P; Brusoni B; Mussini E; Marchetti G
    Arzneimittelforschung; 1986 Feb; 36(2A):304-11. PubMed ID: 3707641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of indoramin on finger blood flow in vasospastic patients.
    Clement DL
    Eur J Clin Pharmacol; 1978 Dec; 14(5):331-3. PubMed ID: 729626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of plasma cholinesterase prevents the dopamine DA-1 receptor mediated renal vasodilation produced by ibopamine.
    Nichols AJ; Shebuski RJ; Ruffolo RR
    Eur J Pharmacol; 1987 Sep; 141(3):515-8. PubMed ID: 3666046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of some renal and cardiovascular effects of a prostaglandin analog, SKF 82526 and ibopamine in anesthetized dogs.
    Seymour AA; Blaine EH
    Arch Int Pharmacodyn Ther; 1984 Jun; 269(2):304-15. PubMed ID: 6148046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology of ibopamine.
    Itoh H
    Am J Med; 1991 May; 90(5B):36S-42S. PubMed ID: 1675550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The acute and chronic effects of indoramin on renal function, hemodynamics, and transport.
    Morrison G; Spar B; Walker BR; Goldfarb S
    J Cardiovasc Pharmacol; 1986; 8 Suppl 2():S25-9. PubMed ID: 2423792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ibopamine on peripheral hemodynamics: a strain gauge plethysmographic study in patients with congestive heart failure.
    Musacci GF; Ansani L; Toselli T; Aggio S; Baracca E; Longhini C
    Arzneimittelforschung; 1986 Feb; 36(2A):380-2. PubMed ID: 3707654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential blockade of alpha-adrenoceptors by indoramin.
    Nicholls DP; O'Connor PC; Harron DW; Leahey WJ; Shanks RG
    Br J Clin Pharmacol; 1984 Jun; 17(6):719-28. PubMed ID: 6146328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of ibopamine treatment in patients with advanced heart failure: purpose of a new therapeutic scheme with multiple daily administrations.
    Dei Cas L; Metra M; Nodari S; Visioli O
    J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S111-7. PubMed ID: 2483436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of the novel inotropic agent, ibopamine, with epinine, dopamine and fenoldopam on renal vascular dopamine receptors in the anesthetized dog.
    Nichols AJ; Smith JM; Shebuski RJ; Ruffolo RR
    J Pharmacol Exp Ther; 1987 Aug; 242(2):573-8. PubMed ID: 2886644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular effects of intravenous indoramin hydrochloride in man.
    Coleman AJ; Leary WP; Asmal AC
    J Int Med Res; 1979; 7(6):511-8. PubMed ID: 520654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracardial effects of oral ibopamine versus furosemide in patients with mild or moderate heart failure. A double-blind, randomized trial.
    Wehling M; Zimmermann J; Theisen K
    Cardiology; 1990; 77 Suppl 5():81-8. PubMed ID: 2279257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of ibopamine on the renal functional response to extracellular volume expansion in man].
    Agnoli GC; Cacciari M; Cariani A; Garutti C; Ikonomu E; Lenzi P
    Cardiologia; 1985 Feb; 30(2):129-37. PubMed ID: 4064065
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of the alpha adrenoceptor activity of dopamine, ibopamine and epinine in the pulmonary circulation of the dog.
    Shebuski RJ; Fujita T; Smith JM; Ruffolo RR
    J Pharmacol Exp Ther; 1987 Apr; 241(1):6-12. PubMed ID: 3033210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the alpha and beta adrenoceptor-mediated activities of the novel, orally active inotropic agent, ibopamine, in the cardiovascular system of the pithed rat: comparison with epinine and dopamine.
    Nichols AJ; Ruffolo RR
    J Pharmacol Exp Ther; 1987 Aug; 242(2):455-63. PubMed ID: 3039117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Renal effects of ibopamine in comparison with furosemide in patients with mild heart failure].
    Wehling M; Zimmermann J; Weil J; Gerzer R; Theisen K
    Z Kardiol; 1990 Feb; 79(2):120-5. PubMed ID: 2157313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal and humoral effects of ibopamine, a dopamine agonist, in patients with liver cirrhosis.
    Salerno F; Incerti P; Badalamenti S; Lorenzano E; Graziani G; Morganti A; Ghirardi P
    Arch Intern Med; 1990 Jan; 150(1):65-9. PubMed ID: 1967522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.